Amerikanische Gesellschaft für Hirudotherapie

Yeast surface display of leech hyaluronidase for the industrial production of hyaluronic acid oligosaccharides

Research article published in Eng Microbiol (2023)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportSpeichel-PharmakologieArzneimittelentwicklungLiao L et al. · Eng Microbiol, 2023

Abstract

Leech hyaluronidase (LHyal) is a hyperactive hyaluronic acid (HA) hydrolase that belongs to the hyaluronoglucuronidase family. Traditionally, LHyal is extracted from the heads of leeches, but the recent development of the Pichia pastoris recombinant LHyal expression method permitted the industrial production of size-specific HA oligosaccharides. However, at present LHyal expressed by recombinant yeast strains requires laborious protein purification steps. Moreover, the enzyme is deactivated and removed after single use. To solve this problem, we developed a recyclable LHyal biocatalyst using a yeast surface display (YSD) system. After screening and characterization, we found that the cell wall protein Sed1p displayed stronger anchoring to the P. pastoris cell wall than other cell wall proteins. By optimizing the type and length of the linkers between LHyal and Sed1p, we increased the activity of enzymes displayed on the P. pastoris cell wall by 50.34% in flask cultures. LHyal-(GGGS)6-Sed1p activity further increased to 3.58 × 105 U mL-1 in fed-batch cultivation in a 5 L bioreactor. Enzymatic property analysis results revealed that the displayed LHyal-(GGGS)6-Sed1p generated the same oligosaccharides but exhibited higher thermal stability than free LHyal enzyme. Moreover, displayed LHyal-(GGGS)6-Sed1p could be recovered easily from HA hydrolysis solutions via low-speed centrifugation and could be reused at least 5 times. YSD of LHyal not only increased the utilization efficiency of the enzyme but also simplified the purification process for HA oligosaccharides. Thus, this study provides an alternative approach for the industrial preparation of LHyal and HA oligosaccharides.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Zusammenfassung

Yeast surface display of leech hyaluronidase using Sed1p anchor; displayed enzyme reaches 3.58 million U/ml and is reusable for at least 5 cycles.

Warum dies für die Hirudotherapie relevant ist

This biotechnology study describes the development of a recyclable leech hyaluronidase (LHyal) biocatalyst using a yeast surface display system in Pichia pastoris, achieving enzymatic activity of 3.58 × 10⁵ U mL⁻¹ in fed-batch cultivation and enabling industrial production of size-specific hyaluronic acid oligosaccharides. LHyal, traditionally extracted from leech heads, was anchored to the yeast cell wall via the Sed1p protein, resulting in improved thermal stability and reusability for at least five cycles. This has indirect relevance to the ASH domain by demonstrating biotechnological applications of a leech-derived enzyme, though the focus is on industrial polysaccharide production. Caveat: This is a protein engineering and industrial bioprocessing study with no therapeutic application, clinical data, or examination of anticoagulant or hirudotherapy-relevant secretome properties.

Zitation

Yeast surface display of leech hyaluronidase for the industrial production of hyaluronic acid oligosaccharides.

Liao L et al. · Eng Microbiol, 2023

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.